This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeoStem To Present At Multiple Conferences In January

NEW YORK, Jan. 2, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that the Company and its subsidiary, Progenitor Cell Therapy ("PCT"), will present at multiple conferences in January.

Biotech Showcase TM 2013
  • Date: January 8, 2013, 4:15 PM PST
  • Venue: Parc 55 Wyndham, San Francisco – Union Square, San Francisco, CA
  • Speaker: Andrew L. Pecora, M.D., FACP, Chief Medical Officer and Director, NeoStem, will present on Amorcyte

Scale-Up and Manufacturing of Cell-Based Therapies II
  • Date: January 22, 2013, 4:50 PM PST
  • Venue: Hyatt Regency Mission Bay Spa and Marina, San Diego, CA
  • Session Title: Cell Therapy Facility Design
  • Speaker: Robert A. Preti, Ph.D., President and Chief Scientific Officer of PCT

Eighth International Conference on Cell Therapy for Cardiovascular Diseases (IC3D 2013)
  • Date: January 24, 2013, 9:30 AM EST
  • Venue: Vivian and Seymour Milstein Family Heart Center, New York City, NY
  • Session Title: AMR-001 Phase 1 Outcome and PreSERVE Study Design: Autologous CD34+ Cells
  • Speaker: Jonathan Sackner-Bernstein, M.D., FACC, Vice President of Clinical Development and Regulatory Affairs, NeoStem

Phacilitate's Cell & Gene Therapy Forum
  • Venue: The Grand Hyatt, Washington, DC
  • Session 1 --  Date: January 28, 2013, 10:40 AM EST --  Session Title: Industry and payer perspectives - What are the current issues that might prevent a cell or gene therapy product candidate from being commercially viable, and how can they be addressed? --  Panelist: Robert A. Preti, Ph.D., President and Chief Scientific Officer of PCT
  • Session 2 --  Date: January 28, 2013, 1:05 PM EST --  Session Title: How to optimize the financial and operational efficiency of an emerging cell therapy business? --  Speaker: Sanjin Zvonic, Ph.D., Director, Technology & Business Development, PCT
  • Session 3 --  Date: January 29, 2013, 3:05 PM EST --  Session Title: Product characterization as a cornerstone of a commercially successful cell therapy product --  Speaker: Timothy Fong, Ph.D., M.B.A., Vice President, Technology & Product Development, PCT

About NeoStem, Inc.

NeoStem, continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift occurring in medicine. We anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy industry. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, PCT, with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe that, with our expertise and research capabilities and collaborations, we will achieve our mission of becoming a premier cell therapy company.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.69 -0.59%
FB $119.49 1.43%
GOOG $711.11 1.40%
TSLA $214.93 1.61%
YHOO $37.23 0.79%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs